1. Home
  2. DOMO vs VNDA Comparison

DOMO vs VNDA Comparison

Compare DOMO & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Domo Inc. Class B

DOMO

Domo Inc. Class B

HOLD

Current Price

$8.91

Market Cap

477.0M

Sector

Technology

ML Signal

HOLD

Logo Vanda Pharmaceuticals Inc.

VNDA

Vanda Pharmaceuticals Inc.

HOLD

Current Price

$7.04

Market Cap

289.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DOMO
VNDA
Founded
2010
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
477.0M
289.0M
IPO Year
2018
2006

Fundamental Metrics

Financial Performance
Metric
DOMO
VNDA
Price
$8.91
$7.04
Analyst Decision
Buy
Strong Buy
Analyst Count
8
3
Target Price
$14.38
$14.00
AVG Volume (30 Days)
1.0M
1.3M
Earning Date
12-04-2025
10-29-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$318,002,000.00
$212,074,000.00
Revenue This Year
$2.32
$12.01
Revenue Next Year
$2.72
$21.57
P/E Ratio
N/A
N/A
Revenue Growth
N/A
11.12
52 Week Low
$6.01
$3.81
52 Week High
$18.49
$7.05

Technical Indicators

Market Signals
Indicator
DOMO
VNDA
Relative Strength Index (RSI) 33.16 70.91
Support Level $8.55 $6.15
Resistance Level $8.97 $7.05
Average True Range (ATR) 0.54 0.47
MACD 0.02 0.10
Stochastic Oscillator 15.03 100.00

Price Performance

Historical Comparison
DOMO
VNDA

About DOMO Domo Inc. Class B

Domo Inc provides a cloud-based platform that digitally connects all the data, systems, and people in an organization, giving them access to real-time data and insights and allowing them to manage their business from their smartphones. The company offers a platform to its customers as a subscription-based service. Users receive notifications on any device and immediately act on the invitation, after which the system can write back to the original system of record. The company derives revenue from subscriptions to its cloud-based platform and professional services.

About VNDA Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

Share on Social Networks: